DC Chemicals

All products / DC7189

LY-2109761
CAT. NO. DC7189

LY-2109761

Pack sizes and prices

Pack sizePrice
100 mg$550 USDRequest a quote / confirm availability →
250 mg$1,000 USDRequest a quote / confirm availability →
1 g$1,800 USDRequest a quote / confirm availability →

Confirm stock, lead time, shipping and final quotation with our team.

Product overview

LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 μM and 20 μM, respectively, which can be strongly enhanced when combined with gemcitabine in combination index value of 0.36581. Blocking TβRI/II kinase activity with LY2109761 (5 μM) completely suppresses both the basal and TGF-β1-stimulated migration and invasion of L3.6pl/GLT cells, significantly enhances the detachment-induced apoptosis by 26% at 8 hours treatment, and completely suppresses TGF-β–induced Smad2 phosphorylation. LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression. LY2109761 pretreatment enhances radiosensitivity of glioblastoma cells via TGF-β signaling blockage. LY2109761 (10 μM) reduces the self-renewal and proliferation of GBM-derived cancer stem–like cells (CSLC), which can be significantly enhanced when combined with radiation. Administration of LY2109761 (50 mg/kg) alone or in combination with gemcitabine (25 mg/kg) significantly reduces the tumor volume by ~70% and ~90%, respectively, prolongs the survival with the median survival duration of 45.0 days and 77.5 days, respectively, and reduces spontaneous abdominal metastases in the L3.6pl/GLT Xenograft mice model. In consistent with the in vitro effect, administration of LY2109761 alone or in combination with radiation, markedly inhibits tumor growth in the orthotopical CSLC glioblastoma model by 43.4% and 76.3%, respectively, decreases tumor invasion and tumor microvessel density, and significantly enhances radiation-induced tumor growth delay in the U87MG xenograft mice model. For the detailed information of LY-2109761, the solubility of LY-2109761 in water, the solubility of LY-2109761 in DMSO, the solubility of LY-2109761 in PBS buffer, the animal experiment (test) of LY-2109761, the cell expriment (test) of LY-2109761, the in vivo, in vitro and clinical trial test of LY-2109761, the EC50, IC50,and Affinity of LY-2109761, Please contact DC Chemicals.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC7189
Product nameLY-2109761
CAS700874-71-1
Molecular formulaC26H27N5O2
Molecular weight441.52
Purity>98%
SMILESc1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — LY-2109761 (DC7189)

Related research products

Browse newly added products